Biolidics lands 5-year licensing deal to develop COVID-19 test kits
Category: #health  By Nikita Chaurasia  Date: 2020-07-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biolidics lands 5-year licensing deal to develop COVID-19 test kits

Biolidics, a precision medicine medical technology company, headquartered in Singapore, on July 9 inked an agreement with the commercialization arm of the Agency for Science, Technology and Research (A*Star), Accelerate Technologies, to use the agency’s COVID-19 viral spike detection technology, cites sources.

Reportedly, under the agreement, Accelerate Technologies is granting non-exclusive worldwide rights to Biolidics for using the technology for diagnostic application and to advance it and market new serology tests that utilize the technology.

Previously, in April, the company obtained authorization for the use of test kits in the Philippines, European Union, and US, and also partnered with the scandal-hit Aytu for distribution of its kits. In the following month, the company appointed Clearbridge Health as a distributor in the Philippines, Myanmar, Indonesia, and Vietnam.

In June, the company reportedly called off the sale of its test kits in the US due to high competition. At the same time, it also announced development of a new test kit in collaboration with Aytu.

With so many variables, the Catalisted-firm is under the close watch of SGX (The Singapore Exchange). Biolidics was inquired on its late announcement as the deal was closed few days ago, whether its sponsor was aware and consulted, and was asked to disclose the advice the sponsor gave as well as its trading halt & announcement timings, cites sources with the knowledge of the matter.

Prior to the agreement with Accelerate Technologies, earlier this month, the company declared its five-year agreement with China's LC-Bio for developing cancer-diagnostic solutions.

The company’s share spiked by 29.3 percent on Monday before its trading halt at 12:19 pm. The A*Star announcement was made at 10:46 pm the following day, before lifting the halt on Wednesday morning before the market’s opening bell.

 

Source: https://www.straitstimes.com/business/companies-markets/biolidics-signs-5-year-licence-with-astar-arm-eyes-development-of-new

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Facebook sued for failing to protect data in Cambridge Analytica breach
Facebook sued for failing to protect data in Cambridge Analytica breach
By Nikita Chaurasia

  The group taking the social media giant to court is ‘Facebook You Owe Us’. Facebook claims to have not received any documents pertaining to the lawsuit. American social media conglomerate Facebook Inc. has reportedly been sue...

Sony witnesses high demand for Play Station 5 through preorders
Sony witnesses high demand for Play Station 5 through preorders
By Nikita Chaurasia

Japanese multinational conglomerate Sony Corporation has reportedly witnessed a high demand for its PlayStation 5 (PS5) console with the pre-orders coming in at an unexpected pace. Market analysts claim that the company intends to lead the competiti...

London’s gearing up to deliver Covid-19 vaccine as early as next week
London’s gearing up to deliver Covid-19 vaccine as early as next week
By Nikita Chaurasia

The George Eliot Hospital NHS Trust, Warwickshire, is likely to receive the first batches of AstraZeneca’s and Oxford’s coronavirus vaccine on 2nd November. The revelation comes along the heels of directive to George Eliot Hospital NHS T...